CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017
Cash Flows from Operating Activities:
Net income	$ 15,907	$ 40,239
Non-cash items:
Depreciation and amortization	51,692	43,986
Impairment of assets	21,170	0
Stock-based compensation expense	7,961	4,199
Gain on divestiture	0	(8,000)
Provision for losses on accounts receivable and inventory	549	688
Other non-cash operating activities	1,277	312
Change in operating assets and liabilities:
Change in accounts receivable	(13,326)	10,739
Change in inventories	(3,912)	7,284
Change in prepaid income taxes	(349)	776
Change in other assets and other liabilities	4,095	3,920
Change in accounts payable and accrued expenses	(4,585)	(6,815)
Net cash provided by operating activities	80,479	97,328
Cash Flows from Investing Activities:
Capital expenditures	(76,002)	(29,125)
Proceeds from divestiture	0	9,000
Proceeds from sale of property, plant and equipment	656	1,346
Net cash used in investing activities	(75,346)	(18,779)
Cash Flows from Financing Activities:
Term loan borrowings	347,780	0
Term loan borrowings	(258,103)	(28,455)
Proceeds from employee stock purchase plan	1,780	1,622
Proceeds from exercise of stock options	7,127	10,120
Share repurchases	(80,000)	0
Other financing activities	0	417
Net cash provided by (used in) financing activities	18,584	(16,296)
Effect of exchange rates on cash and cash equivalents	(4,123)	1,805
Net Change in Cash and Cash Equivalents	19,594	64,058
Cash and Cash Equivalents at Beginning of Period	180,169	139,564
Cash and Cash Equivalents at End of Period	199,763	203,622
Supplemental Disclosures of Cash Flow Information:
Interest paid	5,833	3,768
Income taxes paid	5,053	5,449
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 12,099	$ 3,965